August 4, 2023


CellCarta’s immuno-MRM assays, based on immunoaffinity enrichment of peptides coupled to liquid chromatography-targeted multiple reaction monitoring (LC-MRM), allow for sensitive and precise protein quantification. We offer nine CPTAC validated panels to investigate DNA damage response (DDR1, 2, 3), immuno-oncology (IO-1, 2, 3), Ras-MAPK signaling pathway (Ras-MAPK1, 2), and human epidermal growth factor receptor 2 (HER2) expression. Our team continually develops new panels, combining up to 50 targets (listed below), for your specific needs. With CAP-accredited and CLIA-certified sites, we provide the highest standard of quality.

Contact us for any custom development.


You might also be interested by